Tomatoes Recalled in 14 States Over Salmonella Concerns, FDA Warns
The recall involves two different brands: Ray & Mascari Inc. and Williams Farms Repack LLC. No illnesses have been reported so far, but consumers are urged to avoid consuming the recalled products.
Ray & Mascari Inc., based in Indiana, recalled four-count packs of Vine Ripe tomatoes sold in plastic clamshells. These tomatoes were distributed at Gordon Food Service Stores in 11 states, including New York, Illinois, Pennsylvania, and Michigan.
According to Today , the tomatoes were sold under the label "Vine Ripe Tomatoes" and had the statement "Packed by Ray & Mascari Inc." The affected lot numbers are RM250424 15250B and RM250427 15250B.
Williams Farms Repack LLC, located in South Carolina, also recalled several tomato products. These tomatoes, sold between April 23-28, 2025, were distributed to wholesalers in South Carolina, North Carolina, and Georgia.
Affected products include multiple package sizes of tomatoes, with lot codes R4467, R4470, and others. The tomatoes were sold under Williams Farms Repack and H&C Farms labels. FDA Warns of Salmonella Contamination in Tomatoes, Urges Return
Salmonella is a bacteria that can cause serious illness, especially in young children, the elderly, and people with weakened immune systems. Infections can lead to fever, diarrhea, vomiting, and stomach cramps.
While the FDA has not reported any illnesses connected to the tomatoes, they urge consumers to discard or return the products for a refund.
The tomatoes were supplied by Hanshaw & Caping Farms of Immokalee, Florida, which notified both companies about the possible contamination, CBS News said.
The FDA stated that while no illnesses have been linked to the tomatoes yet, it is crucial for consumers to act quickly to prevent potential health risks.
The affected tomatoes from Ray & Mascari Inc. were sold in the following states: Illinois, Indiana, Kentucky, Michigan, Missouri, Mississippi, New York, Ohio, Pennsylvania, Tennessee, and Wisconsin.
Meanwhile, the Williams Farms tomatoes were sold in South Carolina, North Carolina, and Georgia. If you purchased any of the recalled tomatoes, the FDA advises you to throw them away or return them to the store where you bought them.
For more information or questions, consumers can contact Jason Breland at Williams Farms Repack LLC at 843-866-7707 or 843-599-5154. For Ray & Mascari Inc., the contact number is 317-637-0234.
Originally published on vcpost.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
a day ago
- Int'l Business Times
BetterAlt Rolls Out Its Top Wellness Supplements on Target.com
BetterAlt is expanding its reach, making its line of Ayurveda-inspired supplements available through starting July 29. For shoppers seeking natural routines backed by traditional remedies and modern science, this partnership offers new options in the digital marketplace. The new rollout features BetterAlt's most popular products, each with a unique blend aimed at different health needs. She-lajit Honey Sticks combine shilajit, saffron, and shatavari to promote energy, support hormone balance, improve reproductive health, and aid postnatal wellness for mothers. Shilajit Seamoss All-in-One Capsules are formulated with over ninety essential minerals and ingredients such as ashwagandha, seamoss, panax ginseng, maca root, gingko biloba, zinc, and black pepper. These capsules target everyday strength and vitality, providing broad nutritional support. Ashwagandha Honey Sticks stand out for their use of pure KSM-66 ashwagandha blended with organic honey and natural vanilla. These are designed for individuals who are looking to reduce fatigue, improve focus, relax, and, ultimately, promote deep sleep. For those looking for clean energy, Shilajit Honey Sticks combine 100% pure Himalayan shilajit with organic honey to help boost strength, stamina, nutrient absorption, and mental clarity. The mix brings the natural sweetness of honey together with the earthy profile of shilajit resin in a handy format. Those who prefer a plant-based option can reach for the Pure Shilajit Resin Gummies. These gummies use real tamarind for flavor, skip gelatin in favor of plant-based pectin, and are designed to support energy, boost vitality and strength, regulate hormones, and promote overall wellness. "Our goal has always been to make wellness accessible and real," said Akash Dhoot, co-founder of BetterAlt. "Launching on goes beyond another milestone—it feels like we're stepping right into the dream we started with: making it simple for more people to care for their wellbeing." Building Trust Through Quality and Science BetterAlt's approach is rooted in the principles of Ayurveda and reinforced by scientific research. All products are third-party lab-tested at ISO-certified laboratories, a step that ensures purity and consistent potency. The brand also offers FDA manufacturing certifications to consumers who request them, demonstrating their commitment to transparency and safety. The company's focus on clean, thoughtfully formulated supplements has fueled impressive growth. BetterAlt's Himalayan Shilajit products have reached over fifteen million servings sold, and 1.5 million customers have tried their formulas in just the first year of operations. This digital momentum extends to other popular platforms: the brand is consistently ranked among the top three health brands on TikTok Shop and frequently holds the number one spot in its Amazon categories. Meeting Today's Demand for Accessible Wellness Bringing BetterAlt products to makes high-quality, natural supplements more accessible to shoppers throughout the U.S. This partnership highlights a growing demand for evidence-backed, holistic wellness solutions designed with both heritage and modern lifestyles in mind. With this new availability, more people have the opportunity to prioritize their well-being with trusted, lab-verified, and easy-to-use products. The brand's rise has been marked by rapid growth. Having sold to over a million customers worldwide, BetterAlt has expanded to meet the needs of markets across North America, Asia, and Europe. Headquartered in the United States, the company has managed to secure consistent growth rates and has reached a new peak of its reach through this partnership. "We're excited to welcome BetterAlt to . BetterAlt brings an inspiring and innovative wellness range of products that align perfectly with what our guests are looking for," said a spokesperson from . As BetterAlt continues to build its presence in the wellness market, its focus remains on keeping routines simple, effective, and available to all. The addition of its supplements to is another step in helping customers nationwide find everyday solutions for health and vitality.
Int'l Business Times
29-07-2025
- Int'l Business Times
How Neuromodulation is Reshaping the Treatment of Resistant Mental Health Disorders and Restoring Hope
For decades, the landscape of psychiatric care has remained relatively static, dominated by the long-standing and familiar regimen of antidepressants, SSRIs, and psychotherapy techniques. While these continue to be effective for many, there remains a significant segment of the population that grapples with treatment-resistant depression, suicidality, and complex anxiety disorders. With traditional medical interventions rendered ineffective for those suffering from such mental disorders, they're often left feeling like they have no viable options. This absence of hope further exacerbates their condition, often compounding their emotional experience. But now, a quiet transformation has been taking place, bringing a wave of evidence-backed group of therapies, collectively known as neuromodulation, that is changing the reality and offering a breakthrough for patients long left at the margins of traditional care. Michigan Advanced Psychiatry , a mental health treatment clinic that prioritizes patient care over all else, has made it its mission to normalize and expand access to interventional psychiatry and, in doing so, be the beacon of hope for those seeking it. It offers non-invasive neuromodulation therapies such as Spravato (esketamine), IV ketamine infusions, and Transcranial Magnetic Stimulations (TMS). Contrary to popular belief, these modalities are not experimental outliers. They are FDA-approved, protocol-driven interventions with substantial clinical research backing them. And more importantly, they're known to offer rapid, measurable relief to patients who had all but given up on treatment. "Psychotherapy and pharmacology remain the gold standard to start treatment," says Dr. Drew Schmale, co-founder and board-certified psychiatrist at Michigan Advanced Psychiatry. "But when patients haven't succeeded with the traditional course of treatment, and particularly when suicidality is present, continuing down the same path becomes ineffective, and at times, dangerous. That's where neuromodulation needs to be administered much earlier." Ketamine, or ketamine products like Spravato (esketamine), one of the neuromodulation modalities the company has worked with, has shown remarkable efficacy in patients experiencing major depression and acute suicidal ideation. Unlike conventional antidepressants, which often take weeks to stabilize mood, ketamine's effects have the potential to manifest within hours. Its quick results make it an effective crisis intervention tool available in psychiatry today. "When we have an intervention this powerful, withholding it during a psychiatric crisis becomes a question of ethics," Schmale notes. "We shouldn't be okay with allowing people to stay in any state of suffering for long. Ketamine isn't just treating symptoms; it has the power to save lives." Similarly, TMS is another compelling alternative for those seeking non-pharmaceutical interventions. "A lot of people these days are more interested in non-pharmaceutical options that have very minimal side effects," says Dane Reinhart, co-founder of Michigan Advanced Psychiatry. "And TMS is a great answer for that." Unlike Electro Convulsive Therapy (ECT) , which it's often mistaken for, TMS is a non-invasive, outpatient procedure that uses magnetic pulses to stimulate underactive regions of the brain contributing to depression. There's no anesthesia, no systemic side effects, and patients are able to drive themselves to and from the appointment. "It's about a 20-minute session. You walk in, get the treatment, and walk out. The accessibility and minimal disruption to daily life are a game-changer, and our goal has always been to make it widely available," Reinhart states. Access remains central to Michigan Advanced Psychiatry's foundation, and they've developed a multi-faceted approach to bring that to fruition. The treatments themselves are costly, but the clinic works tirelessly to navigate the entire insurance authorization process, securing coverage for patients. In most cases, this results in patients paying only a modest co-pay for their treatments. For those whose insurance coverage is denied, delayed, or unavailable, they remain committed to providing care. Outside of Spravato and TMS, the clinic offers off-label treatment options, such as IV ketamine, to ensure patients can still receive the help they need. To further remove financial obstacles, they provide flexible payment plans tailored to individual circumstances. "We never want cost to be the barrier," Reinhart says. "Our systems are designed to prioritize patient care above all else." The need for these interventions is global. As Schmale explains, "Mental health treatment has been stagnant for decades. We've recycled the same class of medications under different brand names, hoping for different outcomes. Neuromodulation represents the first meaningful leap forward in a generation." And its benefits stretch well beyond depression. While the clinic currently focuses on depressive disorders, anxiety, OCD, and trauma-related conditions, the science behind neuromodulation is already showing promise across a wider psychiatric spectrum, from bipolar disorder to early-stage psychosis. While both Schmale and Reinhart are quick to note that psychotherapy, medication management, and community-based support still hold substantial value, they believe the future of psychiatry will lie in a more integrated, personalized approach, one that knows when to pivot and how to leverage the best available science at the right moment. "What we're trying to do is evolve without abandoning the roots of our discipline," Schmale adds. "This field must move forward responsibly. Otherwise, it's our patients who pay the price for inertia." At Michigan Advanced Psychiatry , that forward motion is not just philosophy, it's a prerogative. As more providers, insurers, and healthcare systems align around the potential of neuromodulation, Michigan Advanced Psychiatry has established that treatment-resistant no longer means untreatable. The tools exist. The data is here. And for the first time in a long time, psychiatry is not just managing illness; it has the ability to heal them.
Int'l Business Times
17-07-2025
- Int'l Business Times
US Authorizes Juul To Market Vaping Products
Juul Labs said Thursday that the US Food and Drug Administration had officially authorized the e-cigarette maker to market its vaping system and refill capsules in the United States. Juul won the new marketing granting orders (MGO) after submitting more than 110 scientific studies to the agency, the company said in a statement. The decision means Juul can continue to sell products that have been on the US market but in regulatory limbo following earlier actions by the FDA. "Following rigorous evaluation of the data, FDA decided that an MGO for the Juul System was 'appropriate for the protection of public health' -- the standard required by statute for authorization," Juul said. Juul has argued that its vaping products provide a public health benefit by shifting smokers away from combustible tobacco products closely linked to deadly illnesses. But the company has been criticized for its marketing practices, agreeing to pay $438.5 million in a 2022 settlement with 34 US states to resolve accusations of marketing to underage smokers. The FDA's move allows Juul to sell five products in all: the Juul device and capsules for the "Virginia Tobacco" and menthol flavor, each in versions with three or five percent nicotine concentration, said a spokesperson for the US Department of Health and Human Services. The products needed to meet the standard set under a 2009 smoking prevention law showing that the benefits of switching to a potentially less harmful product is "sufficient to outweigh the risks of the product," including to anyone not using tobacco products, the spokesperson said. The applicant submitted data "demonstrating high rates of adults completely switching from cigarettes to either the tobacco- or menthol-flavored Juul products." But the agency's determination "does not mean these tobacco products are safe, nor are they 'FDA approved,'" said the spokesperson, who added that the agency will continue to monitor Juul's compliance with youth marketing restrictions. Juul survived a difficult stretch after the FDA ordered it to halt sales in June 2022 because of health questions, although the decision was adminsistratively suspended by the same agency shortly thereafter. In June 2024, the FDA formally rescinded its June 2022 order, shifting the matter back into "pending" status while a substantive review continued. The FDA's action on Thursday "confirms that these products are now authorized to remain on the market," said a Juul spokesman.
